Coronado's worm therapy fails in Crohn's trial, stock drops 67%
This article was originally published in Scrip
Executive Summary
Shares of Coronado Biosciences lost almost two-thirds of their value on news that the company’s worm therapy failed in a study treating patients with the inflammatory bowel disease Crohn’s.